Physician profile
Mark Levandovsky
NPI 1922267285
$7,131.20
in general payments reported to CMS, 2019-2025
20 companies · $87.57 in 2025
The $87.57 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $178 · 2021: $5,319 · 2022: $872 · 2023: $51.25 · 2024: $90.77 · 2025: $87.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,750.00 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $2,275.92 | 2021 | |
| Amgen INC. | $339.11 | 2019-2025 | Repatha, Repatha |
| Comsort, INC | $100.00 | 2019 | |
| Novo Nordisk INC | $84.33 | 2021-2022 | |
| Genentech USA, INC. | $81.46 | 2019-2020 | |
| Eisai INC. | $75.38 | 2019 | |
| Foundation Medicine, INC. | $69.15 | 2022 | |
| Merck Sharp & Dohme LLC | $61.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.41 | 2019 | |
| Lilly USA, LLC | $46.34 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $36.76 | 2019 | |
| Pfizer INC. | $33.99 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.81 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.71 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $16.81 | 2019 | |
| Cleerly, INC. | $15.46 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Tempus Ai, INC | $14.21 | 2024 | |
| Glaxosmithkline, LLC. | $12.43 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Levandovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.